Investment
Features
FeesSafety
Academy
More
Pluang+

Compare McKesson Corporation (MCK) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance

McKesson CorporationTrade
Recursion Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

McKesson Corporation vs Recursion Pharmaceuticals Inc — how do they compare? McKesson Corporation trades at $895 (market cap $105.14B), while Recursion Pharmaceuticals Inc trades at $3.35 (market cap $1.81B). The key difference: McKesson Corporation is far larger — about 58.1× Recursion Pharmaceuticals Inc's market cap, and McKesson Corporation pays a 0.42% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.

MCKRXRX
Market Cap
$105.14B$1.81B
Sector
HealthHealth
52-Week High
$995.69$6.79
52-Week Low
$659.01$2.84
Enterprise Value
$111.67B$1.33B
Dividend Yield
0.42%

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About McKesson Corporation

McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.

Read more on MCK

About Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.

Read more on RXRX